Crohn's disease related strictures in cross-sectional imaging: More than meets the eye?
- PMID: 36326993
- PMCID: PMC9752301
- DOI: 10.1002/ueg2.12326
Crohn's disease related strictures in cross-sectional imaging: More than meets the eye?
Abstract
Strictures in Crohn's disease (CD) are a hallmark of long-standing intestinal damage, brought about by inflammatory and non-inflammatory pathways. Understanding the complex pathophysiology related to inflammatory infiltrates, extracellular matrix deposition, as well as muscular hyperplasia is crucial to produce high-quality scoring indices for assessing CD strictures. In addition, cross-sectional imaging modalities are the primary tool for diagnosis and follow-up of strictures, especially with the initiation of anti-fibrotic therapy clinical trials. This in turn requires such modalities to both diagnose strictures with high accuracy, as well as be able to delineate the impact of each histomorphologic component on the individual stricture. We discuss the current knowledge on cross-sectional imaging modalities used for stricturing CD, with an emphasis on histomorphologic correlates, novel imaging parameters which may improve segregation between inflammatory, muscular, and fibrotic stricture components, as well as a future outlook on the role of artificial intelligence in this field of gastroenterology.
Keywords: Crohn's disease; computer tomography enterography; cross-sectional imaging; fibrosis; intestinal ultrasound; magnetic resonance enterography; radiomics; strictures.
© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
Conflict of interest statement
Florian Rieder is consultant to Agomab. Allergan, AbbVie, Boehringer Ingelheim, Celgene, Cowen, Falk Pharma, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Origo, Pfizer, Pliant, Prometheus, Receptos, RedX, Roche, Samsung, Takeda, Techlab, Theravance, Thetis, UCB and received funding from the National Institute of Health, Helmsley Charitable Trust, Crohn's and Colitis Foundation, Rainin Foundation, UCB, Boehringer‐Ingelheim, Pliant, Morphic, BMS, 89Bio. Joseph Sleiman receives funding from Pfizer. Prathyush Chirra does not receive funding in conflict with this project. Satish E Viswanath receives funding from Pfizer. Ilyssa O Gordon does not receive and direct funding, but the Cleveland Clinic receives funding on her behalf from Celgene, UCB, GB004, Pliant, Morphic Therapeutics, and Helmsley Charitable Trust. Namita S Gandhi receives funding from Pfizer. Cathy Lu has received consultant/speaker fees from Abbvie, Janssen, Ferring, Takeda, and Fresenius Kabi. Mark E Baker Receives salary support to the Institution from Pfizer and Helmsley Charitable Trust.
Figures
References
-
- Ding NS, Yip WM, Choi CH, Saunders B, Thomas‐Gibson S, Arebi N, et al. Endoscopic dilatation of Crohn's anastomotic strictures is effective in the long term, and escalation of medical therapy improves outcomes in the biologic era. J Crohns Colitis. 2016;10(10):1172–8. 10.1093/ecco-jcc/jjw072 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
